Stroke is the fifth leading cause of death in the Americas. It is also the leading cause of long-term disability in the world. In parallel, the use of photobiomodulation has steadily increased in several areas of medical practice that require healing, prevention of tissue death, pain relief, reduction of inflammation and regenerative medicine. Objectives: this review aims to provide an overview of the use of Photobiomodulation therapies in stroke patients providing the best scientific evidence available to guide future clinical studies and new care protocols in the follow-up and rehabilitation of this population. Methods A scope review according to the extended PRISMA protocol for Systematic Scope Reviews and Meta-analyzes (PRISMA-ScR) limited to English, French, Spanish, Portuguese or Italian, following P.I.C.O. P: (Stroke) I: (Laser OR Photo) in the MEDLINE /, EMBASE, LILACS, Open Gray, Web os Science and Portal Capes databases about Human studies on the use of different types of Photomodulation therapies in patients with Stroke, Ischemic or Hemorrhagic, regardless of the time of injury (acute or chronic) of the comparator or the outcome analyzed. Parallel studies comparing the Laser with control groups without treatment, control groups with sham / placebo therapy, other comparator therapies or NOT control group will be included. No restrictions regarding age, sex of the patient, stroke etiology, time of injury, Light protocol used, type of Light, type of study, intensity, application technique or analyzed outcome will be imposed. Exclusion Criteria: Experimental or animal studies, studies that used other techniques without the use of therapeutic Light, studies with the use of laser as a non-therapeutic diagnostic tool, rapid communications, opinions, editorials, letters to the editor, unpublished studies, journalistic materials, book chapters, published protocols without results, scientific reports without described research methodology, description of patents and products without described research methodology, scientific reports, class records, conferences and lectures, narrative reviews, commercial journals, feeds news, business technical reports, blogs, podcasts and websites. The recommendations recommended in Equator network tools of quality and the REBRATs platform will be used for quality analysis. In addition to the LLT / photomedicine Guideline, we planned the use of the CONSORT Guideline for randomized clinical trials; for non-randomized clinical studies, ROBINS Guideline; for observational studies, STROBE Guideline; for systematic reviews, PRISMA and AMSTAR Guidelines; for case reports, CARE Guideline. If necessary, the NIH Study Quality Assessment Tools and the Cochrane Risk of Bias Tool can be used. The minimum criteria analyzed will be: blinding, presence of a control group, randomization, calculation of the sample size, losses occurred during the study, use of validated instruments for evaluation and diagnosis, clear description of the statistical methods used for objective evaluation, description of the longitudinal follow-up minimum, selective notification of results, prior registration of the study protocol. A qualitative descriptive analysis of the collected data is planned. We planned an individual description of the participants' data and a narrative synthesis. The synthesis will be provided with the results of the included studies, structured around the reported positive or negative results of Laser therapy, the type of intervention, type of conditions studied and study design. Summaries of the effects of the intervention will be provided for each study. If a minimum of two studies with the same material, same condition, therapy and results are found, we plan to use the RevMan software to perform a quantitative synthesis (meta-analysis).